Coherus | search
Click here to view Coherus news from 60+ newspapers.
Bookmark or Share- Coherus | Innovative Immuno-Oncology Therapies | PipelineCoherus is developing a diversified pipeline of immuno-oncology therapeutics that can be part of next-generation treatment combinations to extend survival for patients with cancer across difficult-to-treat tumor types.
- Coherus BioSciences | Novel Immunotherapies for CancerCoherus is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of novel immunotherapies to treat cancer.
- Coherus BioSciences, Inc. (CHRS) - Yahoo FinanceFind the latest Coherus BioSciences, Inc. (CHRS) stock quote, history, news and other vital information to help you with your stock trading and investing.
- Coherus Exits the Biosimilar Business | BR&RIn a final gesture that closes the books on its attempt to become a “pure-play” biosimilar company, Coherus Biosciences has sold off its pegfilgrastim franchise–its last biosimilar asset–to Intas Pharmaceuticals for $558 million.
- Coherus sells Neulasta biosimilar to Intas for up to $558MCoherus has agreed to sell its biosimilar Udenyca—which references Amgen’s febrile neutropenia drug Neulasta—to Intas Pharmaceuticals for up to $558.4 million.
More
